ANCA-associated vasculitis presents the physician with a set of challenging and non-ideal therapeutic options. ANCA-associated vasculitides that are refractory to conventional therapy (namely, cyclophosphamide induction) are next best treated with rituximab (an anti-CD20 antibody). This randomized control trial now addresses the effectiveness of rituximab therapy as a first line agent in the treatment of ANCA-associated vasculitides.

***(Note: Only registered users can read and contribute to the discussion). Click here to register.

***See related teaching resources:
1. Induction Therapy for ANCA-associated vasculitis: Pulse vs. Intravenous Cyclophosphamide
2. ANCA-associated vasculitis: A review


Time Required (estimated): 20 minutes
Title: Rituximab versus Cyclophosphamide in ANCA-associated Renal Vasculitis
Citation: NEJM 2010, Volume 363, pp. 211-20
Date Created: 2010
Revisions: None Indicated
Disclaimers: Cambridge University Hospitals National Health Service Foundation Trust and F. Hoffman-La Roche (see p. 212)
Resource Type: Text


Recommend to a Colleague/Friend


Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Transparent Peer Review
Your reviews are anonymous

GD Star Rating

To learn more about our 6-point transparent peer review system, click here

Rituximab v Cyclophosphamide for Induction in ANCA-associated vasculitis — The RITUXIVAS Trial, 9.2 out of 10 based on 1 rating


More in General Nephrology, Glomerulonephritides (123 of 212 articles)